CTSO : Summary for CYTOSORBENTS COR - Yahoo Finance

U.S. Markets close in 5 hrs 55 mins

Cytosorbents Corporation (CTSO)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.50+0.07 (+1.38%)
As of 9:45AM EDT. Market open.
People also watch
AEMDELTPADXSONCSIGXT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.43
Open5.55
Bid5.40 x 1100
Ask5.50 x 2000
Day's Range5.50 - 5.55
52 Week Range3.87 - 6.90
Volume1,705
Avg. Volume58,145
Market Cap140.38M
Beta0.91
PE Ratio (TTM)-11.73
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 hours ago

    CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference

    MONMOUTH JUNCTION, N.J., March 27, 2017 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

  • PR Newswire5 days ago

    Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board

    MONMOUTH JUNCTION, N.J., March 22, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CAR T-cell cancer immunotherapy pioneer, Dr. Carl H. June, M.D., will join its scientific advisory board to help guide applications of the company's technology in the treatment of cancer. Dr. Carl June, Director of the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine, stated, "Life-threatening inflammation caused by high grade cytokine release syndrome (CRS) has been observed in a wide range of cancer immunotherapies.

  • PR Newswire7 days ago

    CytoSorb® Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy

    MONMOUTH JUNCTION, N.J., March 20, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights recent cases using CytoSorb to successfully treat HLH (hemophagocytic lymphohistiocytosis) and their relevance to cytokine release syndrome (CRS) in cancer immunotherapy.